Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Mallinckrodt
Daiichi Sankyo
Express Scripts
Teva
Queensland Health

Generated: August 21, 2019

DrugPatentWatch Database Preview

Patent: 6,140,059

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,140,059
Title: Methods for the obtention of human immunodeficiency virsus Type 1 envelope glycoproteins in native and oligomeric form employing recombinant chimeric antigens containing collagenase recognition sites.
Abstract:The present invention is relative to a method for the obtention of native domains of viral membrane proteins, especially of native, that is, oligomeric and glycosylated ectodomains of the surface protein gp160 of the human immunodeficiency virus HIV, the causative agent of AIDS (acquired immune deficiency syndrome), as well as the native protein domains themselves obtained by this method, especially native ectodomains of the env glycoprotein of HIV whose monomers exhibit an electrophoretic mobility of approximately 140 kD as well as their use as vaccine, especially as vaccine against HIV. A nucleotide sequence coding for a recognition sequence for protein-splitting enzymes is inserted at a suitable site into the gene coding for the precursor protein of the protein domain to be obtained. After expression of the gene mutant in eukaryotic cells a digestion with a suitable enzyme is carried out and the protein domain to be obtained is subsequently purified.
Inventor(s): Schawaller; Manfred (D-75210 Keltern-Dietlingen, DE)
Assignee:
Application Number:08/448,619
Patent Claims:see list of patent claims

Details for Patent 6,140,059

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04   Try a Free Trial 2013-01-16 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Cantor Fitzgerald
McKinsey
Deloitte
Harvard Business School
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.